New combo aims to keep myeloma in check after CAR t

NCT ID NCT06518551

Recruiting now Disease control Sponsor: Omar Nadeem, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding two drugs (elotuzumab and iberdomide) plus a steroid after CAR T-cell therapy can help control multiple myeloma that has come back or not responded to treatment. About 49 adults who have already tried at least four other treatments will take part. The goal is to see if this approach can delay the cancer's return and improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA MYELOMA REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Brigham and Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.